Skip to main content

Table 3 Outcome of treatment – compliance and relapse

From: Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study

Treatment

No. (%) patients

No. (%) of patients who completed treatment

No. (%) of relapse

SAG

89 (31.56)

13 (14.61)

-

SAG + Allopurinol

56 (19.86)

10 (17.85)

-

SAG + Rifampicin

9 (3.19)

2 (22.23)

Not followed

SAG + Allopurinol + Rifampicin

6 (2.12)

0 (0)

-

SAG + Mw Vaccine

8 (2.83)

2 (25)

-

Miltefosine

107 (37.94)

91 (85.05)

12 (13.18)

Amphotericin B

1 (0.35)

1 (100)

-

Miltefosine + Amphotericin B

6 (2.12)

5 (83.33)

-

Total

282

124 (43.97)

12 (9.67)